FDA Again Delays Approval of Rocket Pharmaceuticals' Gene Therapy Treatment

Rocket Pharmaceuticals' experimental treatment for a rare immune disorder in children was delayed again by the Food and Drug Administration (FDA). Regulators sent a Complete Response Letter to the company, asking for more information on Kresladi. The FDA was initially expected to grant approval in March, but delayed it for three months to complete its review. Rocket Pharmaceuticals (RCKT) shares declined in intraday trading Friday after the biopharmaceutical firm announced that the Food and Drug Administrat ...